OncoMatch/Clinical Trials/NCT03816319
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
Is NCT03816319 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies UAE Inhibitor TAK-243 for myelodysplastic syndrome with excess blasts.
Treatment: UAE Inhibitor TAK-243 — This phase I trial studies the side effects and best dose of TAK-243 in treating patients with acute myeloid leukemia or myelodysplastic syndromes with increased blasts that has come back (relapsed) or that is not responding to treatment (refractory). TAK-243 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Kidney function
Serum creatinine < 176 mcmol/L (2 mg/dL) OR Creatinine clearance > 60 mL/min based on the Cockcroft-Gault equation.
Liver function
Serum bilirubin <= 1.5 × institutional upper limit of normal (ULN); AST/ALT <= 3 × institutional ULN; Patients with a known history of Gilbert's syndrome may enroll.
Cardiac function
Documented normal cardiac function (>= 50%) by echocardiogram or multi-gated acquisition (MUGA) scan.
Serum bilirubin <= 1.5 × institutional upper limit of normal (ULN). Patients with a known history of Gilbert's syndrome may enroll. AST/ALT <= 3 × institutional ULN. Serum creatinine < 176 mcmol/L (2 mg/dL) OR Creatinine clearance > 60 mL/min based on the Cockcroft-Gault equation. Documented normal cardiac function (>= 50%) by echocardiogram or multi-gated acquisition (MUGA) scan.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
- Northwestern University · Chicago, Illinois
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
- VCU Massey Comprehensive Cancer Center · Richmond, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify